Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recibokibart in GPP flare
NCT05512598Phase 1Completed
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HB0034 in generalized pustular psoriasis (GPP), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Number of patients with drug related adverse events at 90 days. Started Nov 2022; status: completed.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT05512598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512598.